PD-1, CTLA-4, LAG3, and TIGIT are very common immunosuppressant sites that have proven to be very beneficial in clinical practices in patients with clinically advanced ccRCC [31–34]. This evidence concerns the gene LAG3 and nonpapillary renal cell carcinoma.